Anahit K. Bakaryan

Anahit K. Bakaryan

Auto-generated profile, based on publicly available information

Anahit K. Bakaryan

H. Buniatian Institute of Biochemistry of NAS of RA, Armenia

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 September 2026 in Proceedings of the YSU B: Chemical and Biological Sciences
Verified
Journal Article
Open access
PDF file
ABAnahit K. Bakaryan
Anahit K. Bakaryan
Adenosine deaminase (ADA) is an enzyme important in mammalian purine metabolism and in maintenance of the immune system. Its activity increases in pathological conditions, resulting in decrease in the concentration of anti-inflammatory adenosine, with aggrаvation of inflammation. Therefore, the discovery and development of ADA inhibitors represent an actual biochemical and pharmacological task. We tested approximately 100 new synthesized aniline and piperazine derivatives for their ADA inhibitory activity. The present study describes the inhibition of ADA by one of the aniline derivatives tested, D011_186. The compound exhibited potent inhibitory activity with an IC50 value of 40±1.1 µg/mL. The interaction between the ADA and D011_186 was investigated using UV-Vis and fluorescence spectroscopy techniques. Differential UV-Vis spectroscopy analysis of the ADA-compound interaction revealed no significant difference between the optical absorption of their mixture relative to the sum of their individual spectra. Next, 2D and 3D fluorescence spectroscopy methods were applied to assess ADA-compound interaction. The individual fluorescence spectra of ADA and compound were compared with the spectrum of their mixture, however, no changes in the recorded fluorescence spectra reflecting their interaction were detected. Thus, although the compound D011_186 inhibits ADA activity it is not accompanied by a change in the orbitals of their optical electrons.

1 June 2026 in Biochemistry (Moscow), Supplement Series B: Biomedical Chemistry
Verified
Journal Article
Closed access
PDF file
AAA. Antonyan
A. Antonyan
RBR. Balagyozyan
R. Balagyozyan
ABA. Bakaryan
A. Bakaryan
AAA. Avetisyan
A. Avetisyan
VMV. Mukuchyan
V. Mukuchyan
SMS. Mardanyan
S. Mardanyan
It was proved that adenosine deaminase (ADA) accumulates in synovial fluids (SFs) in rheumatoid arthritis (RA), reducing the anti-inflammatory adenosine concentration and exacerbating inflammation. Therefore, ADA inhibiting as an inflammation supporting agent may be beneficial in RA treatment. The quest for the new enzyme inhibitors is a relevant task. The aim of this work was to investigate the influence of the water and ethanol extracts of Origanum vulgare L. (OVL) from Armenian landscape on ADA activity. The influence of the extracts on ex vivo ADA activity in two groups of SFs from RA patients with differing the enzyme activity demonstrated more effective inhibition in SFs with higher ADA activity for both extracts. Two isoforms of ADA were purified to elucidate which one is the main factor responsible for the observed enzyme inhibition. There was no significant difference in inhibition of large isoform of ADA from human erythrocytes and RA SFs. The evaluated IC50 values for small isoform of ADA (SADA) evidenced 1.5 times more effective inhibition in vitro citrullinated enzyme compared to the non-citrullinated one. Considering the accumulation of citrullinated SADA in RA SFs enhances inflammation by metabolizing adenosine, the obtained results suggest OVL is a promising source of anti-inflammatory agent for the development of new therapeutic medicines for RA.